| Literature DB >> 35404110 |
Jonathon L Baker1,2, Xiaoyu Tang3, Sandra LaBonte4, Carla Uranga1, Anna Edlund1,2.
Abstract
Streptococcus mutans is considered a primary etiologic agent of dental caries, which is the most common chronic infectious disease worldwide. S. mutans B04Sm5 was recently shown to produce reutericyclins and mutanocyclin through the muc biosynthetic gene cluster and to utilize reutericyclins to inhibit the growth of neighboring commensal streptococci. In this study, examination of S. mutans and muc phylogeny suggested evolution of an ancestral S. mutans muc into three lineages within one S. mutans clade and then horizontal transfer of muc to other S. mutans clades. The roles of the mucG and mucH transcriptional regulators and the mucI transporter were also examined. mucH was demonstrated to encode a transcriptional activator of muc. mucH deletion reduced production of mutanocyclin and reutericyclins and eliminated the impaired growth and inhibition of neighboring streptococci phenotypes, which are associated with reutericyclin production. ΔmucG had increased mutanocyclin and reutericyclin production, which impaired growth and increased the ability to inhibit neighboring streptococci. However, deletion of mucG also caused reduced expression of mucD, mucE, and mucI. Deletion of mucI reduced mutanocyclin and reutericylin production but enhanced growth, suggesting that mucI may not transport reutericyclin as its homolog does in Limosilactobacillus reuteri. Further research is needed to determine the roles of mucG and mucI and to identify any cofactors affecting the activity of the mucG and mucH regulators. Overall, this study provided pangenome and phylogenetic analyses that serve as a resource for S. mutans research and began elucidation of the regulation of reutericyclins and mutanocyclin production in S. mutans. IMPORTANCE S. mutans must be able to outcompete neighboring organisms in its ecological niche in order to cause dental caries. S. mutans B04Sm5 inhibited the growth of neighboring commensal streptococci through production of reutericyclins via the muc biosynthetic gene cluster. In this study, an S. mutans pangenome database and updated phylogenetic tree were generated that will serve as valuable resources for the S. mutans research community and that provide insights into the carriage and evolution of S. mutans muc. The MucG and MucH regulators, and the MucI transporter, were shown to modulate production of reutericyclins and mutanocyclin. These genes also affected the ability of S. mutans to inhibit neighboring commensals, suggesting that they may play a role in S. mutans virulence.Entities:
Keywords: Streptococcus mutans; biosynthetic gene cluster; dental caries; mutanocyclin; oral microbiome; reutericyclin
Mesh:
Substances:
Year: 2022 PMID: 35404110 PMCID: PMC9112991 DOI: 10.1128/jb.00042-22
Source DB: PubMed Journal: J Bacteriol ISSN: 0021-9193 Impact factor: 3.476
FIG 1Comparative genomics of B04Sm5 and the pangenome of S. mutans. (A) Whole-genome alignment of S. mutans B04Sm5 versus the type strains UA159 (− muc) and NN2025 (+ muc). The tree on the left is based on the whole-genome alignment itself. (B) The S. mutans pangenome. Graph showing the gene clusters in the S. mutans pangenome versus the number of genomes that each gene appears in. The core (>90% of genomes), shell (≥10% and ≤90% of genomes), and cloud (<10% of genomes) pangenomes are indicated by the background colors green, gray, and blue, respectively. The location of muc on the graph is indicated by the arrow. (C) S. mutans muc biosynthetic gene cluster (BGC) phylogeny. Concatenated protein sequences of MucA-I across the 35 S. mutans genomes harboring muc were used to construct an unrooted phylogenetic tree of the gene cluster. The three main lineages are colored blue, green, and red. (D) S. mutans phylogeny. Phylogenetic tree of 244 S. mutans genomes based on the concatentated protein sequences of 12 core genes, as described under Materials and Methods. The tree is annotated with three layers indicating the presence of muc, GC0000189 (type A2 lanthipeptide, which was correlated with muc in Fig. S2) and GC00001910 (hybrid nonribosomal peptide synthetase / polyketide synthase [NRPS/PKS], which was correlated with muc in Fig. S2). The presence/absence bars in the muc layer are colored based on the position of the muc BGC of the cognate genome in the muc phylogenetic tree in panel C. S. mutans genomes of interest are labeled (B04Sm5, UA159, UA140-KUMC, UA140-UAB, NN20205, and 35). The full phylogenetic tree, with all leaves labeled, is available in Fig. S3.
FIG 2Deletion of the mucG, mucH, or mucI affects production of mutanocyclin and reutericyclins and growth of B04Sm5. (A) High-performance liquid chromatography (HPLC) profiles of concentrated extracts from the supernatant of the indicated strain. Profiles are cropped to retention times of 17 to 31 min, aligned to the mutanocyclin peak (indicated by the dashed blue line), and presented on the same scale. Red dashed lines indicate the peaks of reutericyclins A, B, and C. The inset shows a zoom of retention times of 27 to 31 min to better illustrate the reutericyclin peaks. Note that unlike the main panel, the profiles in the inset are not to the same scale, and the profile of each strain has a scale bar with the scale of the peaks for reference. (B, C) Growth of the parent strain B04Sm5 and its ΔmucD, ΔmucF, ΔmucG, ΔmucH, and ΔmucI derivatives (B) or complement strains mucG-C, mucH-C, and mucI-C (C) in brain heart infusion (BHI) (n = 8 for each strain). OD600, optical density at 600 nm.
Differential expression of muc in the ΔmucD, ΔmucF, ΔmucG, and ΔmucH strains, compared to B04Sm5 (log2-fold change)
| Name | Locus ID | Gene cluster ID | Gene callers ID | NCBI PGAP accession | NCBI PGAP annotation description |
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|
|
| IBL27_RS09110 | GC_00001982 | 1693 | 2.58564569 | 1.19925521 | −7.1955871 | |||
|
| IBL27_RS09105 | GC_00001981 | 1692 | WP_002277495.1 | Thiolase family protein | 1.32475972 | −1.7582417 | −4.7312389 | |
|
| IBL27_RS09100 | GC_00001980 | 1691 | −2.3188811 | −6.4796598 | ||||
|
| IBL27_RS09095 | GC_00001984 | 1690 | WP_002308266.1 | Nonribosomal peptide synthetase | −14.06934 | −1.5771313 | −1.8548904 | −6.5515393 |
|
| IBL27_RS09090 | GC_00001986 | 1689 | WP_002283498.1 | Polyketide synthase | −3.5433655 | −2.1506834 | −2.0506685 | −5.9316069 |
|
| IBL27_RS09085 | GC_00000014 | 1688 | WP_002277499.1 | HXXEE domain-containing protein | −2.7841312 | −5.865363 | −2.1839221 | |
|
| IBL27_RS09080 | GC_00001987 | 1687 | WP_002283497.1 | TetR/AcrR family transcriptional regulator | −3.9166794 | −3.1611157 | −8.5142069 | −3.5935604 |
|
| IBL27_RS09075 | GC_00001983 | 1686 | WP_002277501.1 | TetR/AcrR family transcriptional regulator | 1.06763813 | −10.557072 | ||
|
| IBL27_RS09070 | GC_00001979 | 1685 | WP_002277502.1 | DHA2 family efflux major facilitator superfamily (MFS) transporter permease subunit | −3.2679608 | −3.2504807 | −1.600364 | −8.524352 |
|
| IBL27_RS09065 | Small multidrug export protein | −2.5618472 | −3.3842254 | −2.6864964 |
FIG 3Loss of mucG, mucH, or mucI affects the ability of B04Sm5 to inhibit the competing, health-associated bacteria S. sanguinis, S. gordonii, and S. mitis. Deferred antagonism assay was performed as described under Materials and Methods. Cultures of the indicated S. mutans strains were spotted on to BHI agar and incubated overnight. Cultures of the indicated competing organism were added to BHI soft agar and used to overlay the plates containing the S. mutans. (A) Three replicate assays were performed, and representatives of the brain heart infusion (BHI) plates with an S. sanguinis overlay are shown. (B to G) Bar graphs representing quantification of the zones of inhibition observed with the indicated S. mutans strain and competing species. Error bars represent the standard deviation, and asterisks denote statistical significance between indicated pairs as determined by a Tukey’s multiple-comparison test following a two-way way analysis of variance (ANOVA). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
Strains, plasmids, and primers used in this study
| Strain, plasmid, or primer | Description (reference[s] or source, if not this study) |
|---|---|
| Strains | |
|
| |
| Genomic type strain (does not encode | |
| Parent strain (encodes | |
|
| |
| Used in deferred antagonism assay (ATCC) | |
| Used in deferred antagonism assay (ATCC) | |
| Used in deferred antagonism assay (ATCC) | |
| Host for the plasmids constructed in this study (New England Biolabs) | |
| Plasmids | |
| Construct containing | |
| Vector backbone to make deletion constructs | |
| Construct to make the Δ | |
| Construct to make the Δ | |
| Construct to make the Δ | |
| Vector backbone containing erythromucin resistance cassette (gift from José Lemos) | |
| Construct to make the | |
| Construct to make the | |
| Construct to make the | |
| Primers | |
| Used to amplify | |
| Used to amplify | |
| Used to make the | |
| Used to make the | |
| Used to make the | |
| Used to make the | |
| Used to make the | |
| Used to make the | |
| Used to make the | |
| Used to make the | |
| Used to make the | |
| Used to make the | |
| Used to make the | |
| Used to make the | |
| Used to make the pmucG-C, | |
| Used to make the pmucG-C, | |
| Used to make the pmucH-C, | |
| Used to make the pmucH-C, | |
| Used to make the pmucI-C, | |
| Used to make the pmucI-C, |